North America Pharmaceutical Packaging Market Report by Material, Product, Countries and Company Analysis 2026-2034

North America Pharmaceutical Packaging Market Size and Forecast

North America Pharmaceutical Packaging Market will grow from US$ 53.91 Billion in 2025 to US$ 100.03 Billion in 2034, at a Compound Annual Growth Rate (CAGR) of 7.11% from 2026 to 2034. Market growth is driven by increasing pharmaceutical production, rising demand for safe and compliant drug packaging, and the expansion of biologics and specialty medicines. Furthermore, growing adoption of smart, sustainable, child-resistant, and tamper-evident packaging solutions is expected to strengthen market demand across North America.

What is Pharmaceutical Packaging and Its Uses & Popularity in North America

Pharmaceutical packaging refers to the specialized containers, closures, labels, cartons, blister packs, bottles, vials, ampoules, prefilled syringes, and other protective systems used to store, transport, identify, and dispense medicines. In North America, pharmaceutical packaging is essential for maintaining drug quality, stability, sterility, and safety throughout the product lifecycle. Packaging is widely used for tablets, capsules, liquids, injectables, biologics, vaccines, specialty medicines, and over-the-counter products. Primary packaging directly protects the drug, while secondary and tertiary packaging support identification, transportation, and supply-chain handling. The U.S. FDA requires tamper-resistant packaging for many OTC medicines and provides guidance concerning child-resistant packaging and labeling.

The market is highly popular across North America because of the region’s advanced pharmaceutical and biotechnology industries, stringent quality regulations, increasing biologics production, and strong demand for convenient drug-delivery formats. The North American pharmaceutical packaging market generated approximately US$52.5 billion in revenue in 2024 and is projected to reach about US$80.5 billion by 2030. Growing adoption of prefilled syringes, blister packs, smart packaging, serialization, and sustainable materials is further strengthening demand.

USA Pharmaceutical Manufacturers in 2025 with Revenue

• Johnson & Johnson (J&J) – US$94.19 billion revenue in 2025. J&J is a major U.S. healthcare and pharmaceutical manufacturer with products across oncology, immunology, neuroscience, cardiovascular disease, and other therapeutic areas.
• Eli Lilly and Company – US$65.18 billion revenue in 2025. Growth was strongly supported by diabetes and obesity medicines, including Mounjaro and Zepbound. Lilly reported 45% revenue growth compared with 2024.
• Merck & Co. – US$65.01 billion revenue in 2025. The company is a leading manufacturer of prescription medicines and vaccines, with Keytruda remaining its major oncology product.
• Pfizer Inc. – US$62.58 billion revenue in 2025. Pfizer develops and manufactures medicines and vaccines across oncology, internal medicine, inflammation and immunology, and infectious diseases.
• AbbVie Inc. – US$61.16 billion revenue in 2025. Its portfolio includes immunology, oncology, neuroscience, aesthetics, and other specialty pharmaceutical products.
• Bristol Myers Squibb (BMS) – US$48.19 billion revenue in 2025. BMS focuses heavily on innovative medicines in oncology, hematology, immunology, cardiovascular disease, and other specialty areas.
• Abbott Laboratories – US$44.33 billion revenue in 2025. Abbott operates across pharmaceuticals, medical devices, diagnostics, and nutrition, with its pharmaceutical activities contributing to its broad healthcare portfolio.
• Amgen Inc. – US$36.80 billion revenue in 2025. The biotechnology company develops and manufactures medicines for serious illnesses, particularly in oncology, cardiovascular disease, inflammation, and bone health.
• Gilead Sciences, Inc. – US$29.40 billion revenue in 2025. Gilead is a leading biopharmaceutical manufacturer, particularly recognized for HIV, viral hepatitis, oncology, and other specialty medicines.
• Regeneron Pharmaceuticals, Inc. – US$14.34 billion revenue in 2025. The U.S. biotechnology company develops and manufactures innovative medicines for areas including ophthalmology, immunology, oncology, and rare diseases.

Growth Drivers of the North America Pharmaceutical Packaging Market

Rising Demand for Biologics and Specialty Medicines

The increasing development and commercialization of biologics, biosimilars, vaccines, cell therapies, and specialty medicines is a major growth driver for pharmaceutical packaging in North America. These products often require sophisticated primary packaging capable of maintaining sterility, chemical stability, and protection from environmental factors. North America accounted for approximately 39.5% of global biopharmaceutical packaging revenue in 2025, highlighting the region’s strong position in this segment. The North American biopharmaceutical packaging market generated around US$9.03 billion in 2025 and is projected to reach approximately US$18.21 billion by 2033, representing a 9.2% CAGR. Demand is particularly increasing for vials, ampoules, cartridges, prefilled syringes, and specialized container-closure systems. The growing use of self-administered therapies is also encouraging pharmaceutical companies to adopt convenient packaging formats that improve dosing accuracy and patient usability. As biologics become an increasingly important part of pharmaceutical pipelines, manufacturers are investing in high-performance glass, plastics, elastomers, and ready-to-use packaging systems, creating substantial opportunities for packaging suppliers throughout North America.

Stringent Regulatory and Product-Safety Requirements

Strict regulatory requirements related to drug safety, contamination prevention, tamper resistance, labeling, and traceability are encouraging pharmaceutical companies to invest in advanced packaging solutions. In the United States, FDA regulations require tamper-resistant packaging for many OTC human drug products, while packaging systems must provide visible evidence if tampering has occurred. Regulatory expectations are also supporting demand for child-resistant packaging, serialization, authentication technologies, and secure labeling. The implementation of pharmaceutical traceability requirements has increased the importance of unique identification and track-and-trace capabilities throughout the supply chain. Consequently, pharmaceutical companies are adopting technologies such as 2D codes, digital printing, RFID, NFC, and tamper-evident seals. These solutions help reduce counterfeiting, diversion, and product-integrity risks while improving supply-chain visibility. Rising regulatory scrutiny is therefore encouraging continuous packaging upgrades rather than relying solely on conventional bottles, cartons, or blister packs. This trend is particularly important in North America because pharmaceutical manufacturers must maintain strict compliance while ensuring medicines remain safe, identifiable, and stable throughout distribution.

Growing Preference for Convenient and Sustainable Packaging

Changing patient preferences and increasing environmental awareness are encouraging pharmaceutical companies to develop packaging that is easier to use while reducing material consumption and environmental impact. Demand is rising for prefilled syringes, autoinjector-compatible containers, blister packs, unit-dose formats, lightweight bottles, and other patient-friendly solutions. These formats can simplify medication administration, improve dosing convenience, and support home-based treatment. At the same time, pharmaceutical packaging manufacturers are investing in recyclable plastics, lightweight materials, paper-based components, and other sustainable alternatives. Market data indicate that plastics and polymers represented the largest pharmaceutical packaging material segment in North America in 2024, while glass was identified as one of the fastest-growing material categories. Sustainability initiatives are becoming increasingly important as pharmaceutical companies seek to reduce packaging waste without compromising sterility, barrier performance, or regulatory compliance. The combination of convenience, patient-centric design, and environmental considerations is therefore accelerating innovation in primary and secondary packaging across the North American pharmaceutical industry.

Challenges of the North American Pharmaceutical Packaging Market

High Manufacturing Costs and Complex Compliance Requirements

High production costs represent a significant challenge for pharmaceutical packaging manufacturers in North America. Pharmaceutical packaging must satisfy demanding requirements related to sterility, material compatibility, barrier protection, extractables and leachables, stability, tamper resistance, and product traceability. Meeting these requirements requires specialized materials, validated manufacturing processes, advanced inspection systems, and extensive quality-control procedures. Packaging manufacturers must also comply with evolving regulatory requirements, which can increase testing, documentation, validation, and certification expenses. Advanced formats such as prefilled syringes, specialty vials, smart labels, and connected packaging generally require greater investment than conventional containers. In addition, fluctuations in the prices of glass, polymers, aluminum, paperboard, and other raw materials can increase manufacturing expenses. These costs may be particularly challenging for smaller packaging suppliers and pharmaceutical companies seeking cost-efficient solutions. As a result, manufacturers must balance product safety and regulatory compliance with affordability while continuously investing in automation, quality systems, sustainable materials, and innovative packaging technologies.

Supply-Chain Disruptions and Sustainability Pressures

Supply-chain uncertainty and sustainability requirements create additional challenges for the North American pharmaceutical packaging industry. Pharmaceutical packaging depends on a wide range of specialized materials, including pharmaceutical-grade plastics, glass, aluminum, elastomers, adhesives, coatings, and paperboard. Shortages or price volatility involving these materials can affect production schedules and increase procurement costs. Sustainability creates another layer of complexity because manufacturers must reduce material consumption and packaging waste without compromising sterility, barrier protection, shelf life, or regulatory performance. For example, switching to recycled or bio-based materials requires extensive testing to confirm that the material remains suitable for pharmaceutical applications. The industry must also manage growing demand for lightweight packaging while maintaining mechanical strength and product protection. These requirements can increase research, qualification, and manufacturing costs. Consequently, pharmaceutical packaging companies are increasingly investing in resilient sourcing strategies, material innovation, recycling technologies, and supplier diversification to manage operational risks while meeting the region’s evolving sustainability expectations.

Pharmaceutical Packaging Launches in North America

1. SCHOTT TOPPAC® infuse Next-Generation Polymer Syringe System – 2025
   SCHOTT Pharma introduced its next-generation polymer syringe system featuring a new tamper-evident cap, functional label, and carton-based secondary packaging. The system is designed to eliminate conventional blister packaging and can incorporate RFID technology for drug traceability and inventory management. SCHOTT says the solution can reduce the carbon footprint of the value chain by up to 58%.
2. Tully Tube™ Paper-Based Pill Packaging – 2024
   Pittsburgh-based Parcel Health launched Tully Tube, an automation-ready, paper-based prescription medication package. The recyclable container uses sustainably sourced paper, incorporates recycled plastic, and is designed to provide humidity, water, and child resistance. The company states that Tully Tube uses 53% less plastic than traditional pill bottles and can reduce carbon emissions by approximately 30%.
3. Nelipak North American Flexible Pharmaceutical Packaging – 2024
   Nelipak opened its first North American flexible packaging production facility in Winston-Salem, North Carolina, in November 2024. The site produces healthcare flexible packaging including custom roll-stock, die-cut lids and sheets, pouches, and bags for pharmaceutical and medical applications. The facility strengthens the company’s ability to supply customers throughout the Americas.
4. Schreiner MediPharm Cap-Lock Blister-Free Syringe Packaging – 2025
   Schreiner MediPharm, together with SCHOTT Pharma and Körber Pharma, introduced a blister-free packaging concept for prefilled syringes. The system combines the SCHOTT TOPPAC® infuse COC syringe, a specialized cap, and the Cap-Lock functional label. The solution is designed to reduce packaging material, optimize transportation and storage space, and improve product security.
5. Berry Global Complete Pharmacy Packaging Line – 2024
   Berry Global expanded its pharmaceutical packaging offering with a complete line of pharmacy packaging solutions, including vials, prescription oval bottles, packer bottles, ointment jars, and matching closures. The portfolio is designed for both manual filling and automated central-fill applications, while child-resistant closure options support pharmaceutical safety requirements.
6. BD Neopak™ XtraFlow Glass Prefillable Syringe – 2025
   Becton Dickinson unveiled the Neopak XtraFlow glass prefillable syringe at Pharmapack 2025. The syringe uses a thinner-wall design intended to support the delivery of biologics and GLP-1 therapies while reducing injection force. Its introduction reflects growing demand for specialized primary packaging for high-value injectable medicines.
7. Exela Pharma Sciences Prefilled Syringe Packaging with Tamper-Evident Labels – 2025
   Exela Pharma Sciences launched a series of prefilled syringe products using plastic cyclic olefin copolymer (COC) syringes with customized tamper-evident labeling. IL Group developed the labeling solution to address regulatory and patient-safety requirements while remaining compatible with Exela’s existing production processes.
8. Amcor Recyclable PE Pharmaceutical Blister Packaging – 2024
   Amcor introduced a fully recyclable polyethylene blister-pack concept for prescription medications in 2024. The solution was developed to reduce plastic waste while maintaining the barrier performance and protection required for pharmaceutical products. The development highlights the industry’s shift toward recyclable primary packaging materials.
9. Bormioli Pharma Expanded North American Pharmaceutical Packaging Capacity – 2024
   Bormioli Pharma expanded its North American operations following a reported 47% increase in North American sales in 2023. The company strengthened its U.S. presence through expanded capacity, an FDA-approved warehouse, and product offerings aligned with regional pharmaceutical packaging requirements.
10. Körber–Rondo-Pak Sustainable Pharmaceutical Packaging Expansion – 2024
    Körber Pharma expanded its North American pharmaceutical packaging capabilities through its majority acquisition of Rondo-Pak, a New Jersey-based printing and packaging company. Completed in February 2024, the transaction strengthened Körber’s capabilities in pharmaceutical and biotech packaging, particularly sustainable packaging solutions for customers across North America.

Strong Pharmaceutical Manufacturing and Biologics Demand in USA

United States Pharmaceutical Packaging Market represents the largest market in North America, supported by the country’s extensive pharmaceutical manufacturing base, advanced healthcare infrastructure, and strong demand for prescription and specialty medicines. Increasing production of biologics, vaccines, injectables, and specialty medicines is generating demand for vials, prefilled syringes, blister packs, cartridges, and temperature-sensitive packaging. FDA requirements for tamper-resistant packaging, labeling, and product security further encourage manufacturers to adopt advanced packaging technologies. Serialization, 2D barcodes, smart labels, and anti-counterfeit systems are increasingly used to improve traceability and supply-chain security. Meanwhile, pharmaceutical companies are investing in recyclable plastics, lightweight materials, and sustainable paper-based packaging. Leading suppliers, including Amcor, WestRock, and Gerresheimer, continue to strengthen their portfolios through innovation and capacity expansion. Rising healthcare spending, e-pharmacy adoption, and home-based medication use are expected to sustain market growth.

Canada Expanding Pharmaceutical Industry and Sustainable Packaging Adoption

Canada Pharmaceutical Packaging Market is expanding steadily due to increasing pharmaceutical manufacturing, healthcare spending, specialty-drug consumption, and demand for safe medication delivery. Canada’s pharmaceutical manufacturing industry includes hundreds of establishments involved in pharmaceutical and medicinal product production, creating sustained demand for primary, secondary, and tertiary packaging solutions. Health Canada regulations covering labeling, safety, traceability, and packaging quality encourage pharmaceutical companies to adopt compliant and reliable packaging systems. Growing use of biologics, injectables, vaccines, and specialty medicines is supporting demand for glass vials, prefilled syringes, blister packs, bottles, and temperature-controlled packaging. The expansion of online pharmacies and home-delivery services is also increasing requirements for durable, tamper-evident, and patient-friendly packaging. Sustainability is becoming increasingly important, with manufacturers exploring recyclable polymers, lightweight containers, paper-based packaging, and reduced-material designs. Smart packaging technologies, including QR codes and digital identification, are gaining attention for improving patient information and supply-chain visibility. However, smaller market scale, imported raw materials, higher logistics costs, and regulatory compliance expenses remain challenges. Continued pharmaceutical innovation and healthcare investment should support long-term market development.

North America Pharmaceutical Packaging Market Segments:

Material

• Plastics & Polymers
• Paper & Paperboard
• Glass
• Aluminum Foil
• Others

Product

• Bottles
• Caps & Closures
• Pre-Filled Syringes
• Vials & Ampoules
• Jars & Canisters
• Blister Packs
• Pre-Filled Inhalers
• Cartridges
• Bags & Pouches
• Others

Country

• United States
• Canada

All companies have been covered from 5 viewpoints:

• Company Overview
• Key Persons
• Recent Development & Strategies
• SWOT Analysis
• Sales Analysis

Key Players Analysis

• Amcor PLC
• 3M Company
• Schott AG
• WestRock Company
• Berry Global Group Inc.
• McKesson Corporation
• AptarGroup Inc.
• Klockner Pentaplast Group
• CCL Industries Inc.
• FlexiTuff International Ltd

Report Details: